leisure time -WSS

leisure time

author：fashion 2025-09-30 17:44:09 - browse：38717

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： AstraZeneca chief proposes a novel edit to the drug pricing bill

Wikipedia

WSS

A new House health package & hospitals’ new site

Why Novartis is changing the name of its research labs

Experts study whether long Covid risk adds up with each reinfection

Illumina names Agilent executive as new CEO

Illumina names Agilent executive as new CEO

European officials brace for rough respiratory virus season

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Moonlake's readout produced a cash windfall. Risks remain

The biotech scorecard for Q4: 16 stock

Tori Bowie and the unacceptable rates of Black maternal death

2023 Nobel Prize in Medicine goes to Karikó and Weissman

In Memoriam: Notable people who died in 2023

The stability of $0 premiums in Medicare Advantage

Cancer drug shortages should be causing more outrage

What will Novo Nordisk's VC do with its influx of cash?

In age of alternative facts, a scholarly course on calling out crap

Humana sues Biden admin over Medicare Advantage audit rule

focus

The 10 drugs up first for Medicare price negotiation

Setback for rare diseases as Taysha Gene Therapies pulls back

Stop Congress from blocking public access to science

NIH nominee Bertagnolli will get October confirmation hearing

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Illumina names Agilent executive as new CEO

explore

Wikipedia

entertainment

focus